Skip to main content
Premium Trial:

Request an Annual Quote

Joseph Turgeon, Mary Holland, David Macdonald, Regina Herzlinger, Blaine Bowman, Richard Morris


Nanogen has hired Joseph Turgeon as its new vice president of operations and Mary Holland as its senior director of worldwide corporate accounts. Prior to joining Nanogen, Turgeon served as vice president of operations at Progeny Systems and Medical Electronics Systems of San Diego, the same companies which Nanogen’s new senior vice president of operations, David Macdonald, formerly headed. Turgeon was also director of operations at the Nichols Institute, a subsidiary of Quest Diagnostics. Holland comes to Nanogen from Third Wave Technologies, where she served in senior sales and marketing positions for seven years and was also a co-founder of Oncogenetics, a genetics and cancer diagnostics research laboratory.

Nanogen also recently announced that Regina Herzlinger has stepped down from her position on the company’s board of directors.


Microtransponder array startup PharmaSeq of Monmouth Junction, NJ, appointed Blaine Bowman and Richard Morris to its board of directors. Bowman is president and CEO of Dionex, the ion chromatography company that recently made a $3 million investment in PharmaSeq. Morris is the CEO of PharmaSeq, and joined the company in January.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.